Merck KGaA's MilliporeSigma drops €300M on Korean biologics plant with plans to create 300 new jobs

A little less than a year after Merck KGaA unveiled designs on a new bioprocessing plant in South Korea, the company’s U.S.- and Canada-based life sciences business, MilliporeSigma, has swooped in with a hefty investment at the site and the promise of hundreds of new jobs.